Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF‐κB and TNF‐α/TNFR1/NF‐κB pathways
British Journal of Pharmacology2020Vol. 177(22), pp. 5224–5245
Citations Over TimeTop 10% of 2020 papers
Xiang Xu, Hu‐Nan Piao, Fumie Aosai, Xiao‐Yu Zeng, Jiahui Cheng, Yue‐Xian Cui, Jing Li, Juan Ma, Hu‐Ri Piao, Xuejun Jin, Lian Xun Piao
Abstract
Arctigenin has antidepressant-like effects by attenuating excessive microglial activation and neuroinflammation through the HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB signalling pathways. This suggests that arctigenin has potential as a new drug candidate suitable for clinical trials to treat depression.
Related Papers
- → The HMGB1–TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis(2013)138 cited
- → Potential anti-inflammatory effect of anti-HMGB1 in animal models of ICH by downregulating the TLR4 signaling pathway and regulating the inflammatory cytokines along with increasing HO1 and NRF2(2021)7 cited
- → Toll-like receptor 4 (TLR4) and interferon-gamma (IFN-r) are required for HMGB1-induced TNF release from macrophages. (34.18)(2010)1 cited
- → 68. Mechanisms of Toll-Like Receptor 4- Mediated Inflammation After Cold Ischemia/Reperfusion (I/R)Role of CD14 and HMGB1(2008)
- → The time related concentration of serum HMGB1 and TLR4 in CLP rat model(2018)